Tirzepatide significantly reduces the apnea-hypopnea index (AHI) in adults with obstructive sleep apnea (OSA) and obesity, according to a phase 3 trial published in the New England Journal of Medicine. The study found that patients receiving the drug experienced a substantial decrease in sleep apnea severity and a higher percentage of patients achieving complete resolution of the condition compared to a placebo group.
Tirzepatide Reduces Sleep Apnea Severity in SURMOUNT-OSA Trial
The SURMOUNT-OSA trial, a randomized, double-blind, placebo-controlled study, tested the efficacy of tirzepatide—a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors—in treating obstructive sleep apnea. According to the New England Journal of Medicine, the primary endpoint was the change in the apnea-hypopnea index (AHI) from baseline to week 52.
Participants in the tirzepatide group showed a marked reduction in AHI, which measures the number of times breathing stops or becomes shallow per hour of sleep. The data indicates that weight loss induced by the medication correlates directly with the improvement of upper airway stability during sleep. This suggests that the drug’s ability to reduce adipose tissue in the neck and abdominal areas mitigates the collapse of the airway.
Clinical Outcomes and Resolution Rates
The trial revealed a stark contrast between the treatment and placebo arms regarding the total resolution of OSA. A significant proportion of patients treated with tirzepatide achieved an AHI of less than 5 events per hour, the clinical threshold for a normal sleep profile. In contrast, the placebo group showed minimal improvement in AHI scores.
Beyond the primary AHI metric, the study tracked the use of Continuous Positive Airway Pressure (CPAP) machines. Many participants reported a decreased reliance on CPAP therapy or a total cessation of its use as their sleep apnea symptoms resolved. The U.S. Food and Drug Administration (FDA) previously approved tirzepatide (marketed as Zepbound for obesity and Mounjaro for diabetes) for chronic weight management, but this trial specifically targets the comorbidities associated with obesity, such as OSA.
Comparison of Tirzepatide and Traditional OSA Treatments
Traditional treatment for obstructive sleep apnea focuses on mechanical intervention rather than metabolic correction. The following table contrasts the approach of tirzepatide with standard care:
| Feature | CPAP Therapy | Tirzepatide (SURMOUNT-OSA) |
|---|---|---|
| Mechanism | Mechanical pressure keeps airway open | Weight loss reduces airway obstruction |
| Application | Nightly use of a mask and machine | Once-weekly subcutaneous injection |
| Goal | Symptom management | Disease modification via weight reduction |
| Compliance | Often low due to discomfort | Dependent on medication adherence |
Safety Profile and Patient Considerations
The safety profile of tirzepatide in the SURMOUNT-OSA trial aligns with previous findings in the SURMOUNT weight-loss trials. The most commonly reported adverse events were gastrointestinal in nature, including nausea, diarrhea, and vomiting. According to the trial data, these side effects were generally mild to moderate and occurred primarily during the dose-escalation phase.
Medical professionals note that while tirzepatide offers a pharmacological path to reducing OSA severity, it is not a replacement for immediate stabilization in patients with severe, life-threatening apnea. The drug requires consistent long-term use to maintain weight loss and the subsequent improvements in respiratory function.
Frequently Asked Questions
Does tirzepatide cure sleep apnea?
The SURMOUNT-OSA trial showed that a significant percentage of patients achieved “resolution” of OSA (AHI < 5). However, the study focuses on the reduction of severity and the resolution of symptoms tied to obesity. Whether this constitutes a permanent cure depends on the patient’s ability to maintain weight loss.
Can I stop using my CPAP machine if I start tirzepatide?
Patients should not discontinue CPAP therapy without a physician’s supervision. The trial showed that many patients could reduce or stop CPAP use, but this must be verified by a follow-up sleep study to ensure the airway remains stable.
Who is the ideal candidate for this treatment?
The trial specifically targeted adults with obesity and moderate-to-severe obstructive sleep apnea. Those whose OSA is caused by non-weight-related factors (such as craniofacial abnormalities) may not see the same results.
The results of the SURMOUNT-OSA trial signal a shift toward treating the metabolic drivers of sleep disorders. As clinical data continues to emerge, tirzepatide may become a primary therapeutic option for reducing the burden of obstructive sleep apnea in the obese population.
Worth a look